Keyword Analysis & Research: kras inhibitor


Keyword Analysis

Keyword CPC PCC Volume Score Length of keyword
kras inhibitor0.170.475349214
kras0.730.76089484
inhibitor1.830.6522479

Keyword Research: People who searched kras inhibitor also searched

Keyword CPC PCC Volume Score
kras inhibitor1.220.8399258

Search Results related to kras inhibitor on Search Engine

  • Sotorasib is First KRAS Inhibitor Approved by FDA - NCI

    cancer.gov

    https://www.cancer.gov/news-events/cancer-currents-blog/2021/fda-sotorasib-lung-cancer-kras

    WebJun 25, 2021 · FDA has approved the first KRAS-blocking drug, called sotorasib (Lumakras). The approval, which covers the use of sotorasib for some patients with advanced lung cancer, was based on the results of the CodeBreak100 trial. It also sets the stage for additional KRAS inhibitors already in development, researchers said.

    DA: 73 PA: 2 MOZ Rank: 36

  • Pan-KRAS inhibitor disables oncogenic signalling and tumour …

    nature.com

    https://www.nature.com/articles/s41586-023-06123-3

    WebMay 31, 2023 · KRAS is one of the most commonly mutated proteins in cancer, and efforts to directly inhibit its function have been continuing for decades. The most successful of these has been the development...

    DA: 69 PA: 20 MOZ Rank: 19

  • A single inhibitor for all KRAS mutations | Nature Cancer

    nature.com

    https://www.nature.com/articles/s43018-023-00615-x

    WebAug 24, 2023 · 5 Citations. 40 Altmetric. Metrics. The recent design of mutation-selective KRAS inhibitors has led to US Food and Drug Administration approval of two inhibitors of KRAS (G12C), sotorasib and...

    DA: 18 PA: 86 MOZ Rank: 81

  • Targeting KRAS in cancer | Nature Medicine

    nature.com

    https://www.nature.com/articles/s41591-024-02903-0

    Web6 days ago · BI-2865 is a novel pan-KRAS inhibitor that selectively binds a spectrum of KRAS mutations and the wild-type KRAS protein, but notably spares other RAS family proteins, thereby potentially limiting ...

    DA: 56 PA: 12 MOZ Rank: 84

  • KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa1917239

    WebSep 20, 2020 · Sotorasib (AMG 510) is a small molecule that specifically and irreversibly inhibits KRAS G12C through a unique interaction with the P2 pocket (Fig. S1 in the Supplementary Appendix, available...

    DA: 9 PA: 80 MOZ Rank: 46

  • Sotorasib in KRAS p.G12C–Mutated Advanced Pancreatic Cancer

    nejm.org

    https://www.nejm.org/doi/full/10.1056/NEJMoa2208470

    WebDec 21, 2022 · VOL. 388 NO. 1. Abstract. Background. KRAS p.G12C mutation occurs in approximately 1 to 2% of pancreatic cancers. The safety and efficacy of sotorasib, a KRAS G12C inhibitor, in previously...

    DA: 10 PA: 14 MOZ Rank: 39

  • Annual review of KRAS inhibitors in 2022 - PubMed

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/36680986/

    WebMar 5, 2023 · With the stage now set for a new era in the treatment of KRAS-driven cancers, the development of KRAS inhibitors also enters a booming epoch. In this review, we overviewed the research progress of KRAS inhibitors with the potential to treat cancers covering articles published in 2022.

    DA: 85 PA: 26 MOZ Rank: 70

  • The path to the clinic: a comprehensive review on direct KRAS

    biomedcentral.com

    https://jeccr.biomedcentral.com/articles/10.1186/s13046-021-02225-w

    WebJan 19, 2022 · Adagrasib (MRTX849) and other direct KRAS G12C inhibitors are currently being investigated in multiple clinical trials. In this review, we delve into the path leading to the development of this novel KRAS inhibitor, starting with the discovery, structure, and function of the RAS family of oncoproteins.

    DA: 64 PA: 57 MOZ Rank: 29

  • Targeting KRAS in Cancer: Promising Therapeutic Strategies

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7999304/

    WebMar 10, 2021 · Since the Kirsten rat sarcoma viral oncogene homolog ( KRAS) is mutated in about 25% of all human cancers and is at the center of pathways involved in tumorigenesis, it is necessary to compile and highlight the novel therapeutic strategies behind targeting this oncoprotein in cancer.

    DA: 34 PA: 12 MOZ Rank: 69

  • Drugging KRAS: current perspectives and state-of-art review

    biomedcentral.com

    https://jhoonline.biomedcentral.com/articles/10.1186/s13045-022-01375-4

    WebOct 25, 2022 · Covalent inhibitors that block mutant KRAS G12C were successfully developed and sotorasib was the first KRAS G12C inhibitor to be approved, with several more in the pipeline. Simultaneously, effects of KRAS mutations on tumour microenvironment were also discovered, partly owing to the universal use of immune …

    DA: 98 PA: 5 MOZ Rank: 64